Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVET: Oral Anticoagulants for Extended VTE Treatment
NCT03196349Phase 4Terminated
- Sponsor
- Duke University
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban and rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Duke University. Primary endpoints: Number of Subjects With Clinically Relevant Bleeding Events at 12 months and Number of Subjects With Recurrent Venous Thromboembolism (VTE) at 12 months. Started Aug 2018; status: terminated.
02
Drugs
apixabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03196349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196349.